Circumventing antivector immunity by using adenovirus-infected blood cells for repeated application of adenovirus-vectored vaccines: Proof of concept in rhesus macaques

Journal of Virology

Volumn 86, Issue 20, 2012, Pages 11031-11042

  Sun, Caijun ^a,b   Feng, Liqiang ^a,b   Zhang, Yinfeng ^a   Xiao, Lijun ^a   Pan, Weiqi ^b   Li, Chufang ^b   Zhang, Linqi ^c   Chen, Ling ^a,b  

^a GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

^c TSINGHUA UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRAL VECTOR INFECTION PERIPHERAL BLOOD CELLM MONONUCLEAR CELL VACCINE; ADENOVIRUS VECTOR; CD14 ANTIGEN; GAG PROTEIN; NEUTRALIZING ANTIBODY; POL PROTEIN; UNCLASSIFIED DRUG; VACCINE; VIRUS ENVELOPE PROTEIN;

ADENOVIRUS 5; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IN VITRO STUDY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RHESUS MONKEY; VIRUS LOAD;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, CD14; GENE PRODUCTS, ENV; GENE PRODUCTS, GAG; GENE PRODUCTS, POL; GENETIC VECTORS; HUMANS; LEUKOCYTES, MONONUCLEAR; MACACA MULATTA; SAIDS VACCINES; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINES, ADENOVIRUS; VIRAL VACCINES;

ADENOVIRIDAE; MACACA; MACACA MULATTA; PRIMATES; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 84869015278     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00783-12     Document Type: Article

References (63)

1. Ambrose Z, KewalRamani VN, Bieniasz PD, Hatziioannou T. 2007. HIV/AIDS: in search of an animal model. Trends Biotechnol. 25:333-337.
2. Aste-Amézaga M, et al. 2004. Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene: application in epidemiologic studies and in the design of adenovector vaccines. Hum. Gene Ther. 15:293-304.
3. Bangari DS, Mittal SK. 2006. Current strategies and future directions for eluding adenoviral vector immunity. Curr. Gene Ther. 6:215-226.
4. Benlahrech A, et al. 2009. Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. Proc. Natl. Acad. Sci. U. S. A. 106:19940-19945.
5. Betts MR, et al. 2006. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107:47814789.
6. Bogers WM, et al. 2008. Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge. Virology 382:217-225.
7. Brown K, et al. 2003. Adenovirus-transduced dendritic cells injected into skin or lymph node prime potent simian immunodeficiency virus-specific T cell immunity in monkeys. J. Immunol. 171:6875-6882.
8. Casimiro DR, et al. 2003. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replicationdefective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J. Virol. 77:6305-6313.
9. Casimiro DR, et al. 2005. Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing Gag. J. Virol. 79:15547-15555.
10. Chen L, et al. 1995. Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter. J. Clin. Invest. 96:2775-2782.
11. Chen L, et al. 1996. Selective transgene expression for detection and elimination of contaminating carcinoma cells in hematopoietic stem cell sources. J. Clin. Invest. 98:2539-2548.
12. Cohen J. 2007. Did Merck's failed HIV vaccine cause harm? Science 318: 1048-1049.
13. De Rose R, et al. 2008. Delivery of immunotherapy with peptide-pulsed blood in macaques. Virology 378:201-204.
14. De Rose R, et al. 2008. Control of viremia and prevention of AIDS following immunotherapy of SIV-infected macaques with peptide-pulsed blood. PLoS Pathog. 4:e1000055. doi:10.1371/journal.ppat.1000055.
15. Engram JC, et al. 2009. Vaccine-induced, simian immunodeficiency virus-specific CD8+T cells reduce virus replication but do not protect from simian immunodeficiency virus disease progression. J. Immunol. 183: 706-717.
16. Fitzgerald JC, et al. 2003. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J. Immunol. 170:1416-1422.
17. Gahéry-Ségard H, et al. 1998. Immune response to recombinant capsid proteins of adenovirus in humans: anti-fiber and anti-penton base antibodies have a synergistic effect on neutralizing activity. J. Virol. 72:2388-2397.
18. Ghosh SS, Gopinath P, Ramesh A. 2006. Adenoviral vectors: a promising tool for gene therapy. Appl. Biochem. Biotechnol. 133:9-29.
19. Gorelick RJ, et al. 2000. Protection of Macaca nemestrina from disease following pathogenic simian immunodeficiency virus (SIV) challenge: utilization of SIV nucleocapsid mutantDNAvaccines with and without an SIV protein boost. J. Virol. 74:11935-11949.
20. Hansen SG, et al. 2009. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat. Med. 15:293-299.
21. Heeney JL, Plotkin SA. 2006. Immunological correlates of protection from HIV infection and disease. Nat. Immunol. 7:1281-1284.
22. Herold J, Tillmanns H, Xing Z, Strasser RH, Braun-Dullaeus RC. 2006. Isolation and transduction of monocytes: promising vehicles for therapeutic arteriogenesis. Langenbecks Arch. Surg. 391:72-82.
23. Hong SS, Habib NA, Franqueville L, Jensen S, Boulanger PA. 2003. Identification of adenovirus (Ad) penton base neutralizing epitopes by use of sera from patients who had received conditionally replicative Ad (Addl1520) for treatment of liver tumors. J. Virol. 77:10366-10375.
24. Hutnick NA, et al. 2009. Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4+ T cells. Nat. Med. 15:876-878.
25. Kalams SA. 2003. Cellular immunity for prevention and clearance of HIV infection. Curr. Mol. Med. 3:195-208.
26. Leen A, et al. 2007. Contact-activated monocytes: efficient antigen presenting cells for the stimulation of antigen-specific T cells. J. Immunother. 30:96-107.
27. Lemiale F, et al. 2007. Novel adenovirus vaccine vectors based on the enteric-tropic serotype 41. Vaccine 25:2074-2084.
28. Leopold PL, Wendland RL, Vincent T, Crystal RG. 2006. Neutralized adenovirus-immune complexes can mediate effective gene transfer via an Fc receptor-dependent infection pathway. J. Virol. 80:10237-10247.
29. Letvin NL, et al. 2007. No evidence for consistent virus-specific immunity in simian immunodeficiency virus-exposed, uninfected rhesus monkeys. J. Virol. 81:12368-12374.
30. Liu J, et al. 2009. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 457:87-91.
31. Lun WH, et al. 2004. Loss of virus-specific CD4(+) T cells with increases in viral loads in the chronic phase after vaccine-based partial control of primary simian immunodeficiency virus replication in macaques. J. Gen. Virol. 85:1955-1963.
32. Lyakh LA, et al. 2002. Adenovirus type 5 vectors induce dendritic cell differentiation in human CD14+ monocytes cultured under serum-free conditions. Blood 99:600-608.
33. Lyons M, et al. 2006. Adenovirus type 5 interactions with human blood cells may compromise systemic delivery. Mol. Ther. 14:118-128.
34. Maness NJ, et al. 2008. Comprehensive immunological evaluation reveals surprisingly few differences between elite controller and progressor Mamu-BZ.ast;17-positive simian immunodeficiency virus-infected rhesus macaques. J. Virol. 82:5245-5254.
35. Mason RD, et al. 2009. Inactivated simian immunodeficiency viruspulsed autologous fresh blood cells as an immunotherapy strategy. J. Virol. 83:1501-1510.
36. Mayne GC, et al. 2003. Centrifugation facilitates transduction of green fluorescent protein in human monocytes and macrophages by adenovirus at low multiplicity of infection. J. Immunol. Methods 278:45-56.
37. McCoy K, et al. 2007. Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors. J. Virol. 81:6594-6604.
38. Molnar-Kimber KL, et al. 1998. Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. Hum. Gene Ther. 9:2121-2133.
39. Moog C. 2008. Immune responses that correlate with HIV-1 protection? AIDS 22:1461-1462.
40. Morgan C, et al. 2008. The use of nonhuman primate models in HIV vaccine development. PLoS Med. 5:e173. doi:10.1371/journal. pmed.0050173.
41. Nguyen-Pham TN, Lee YK, Kim HJ, Lee JJ. 2012. Immunotherapy using dendritic cells against multiple myeloma: how to improve? Clin. Dev. Immunol. 2012:397648.
42. Nwanegbo E, et al. 2004. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin. Diagn. Lab. Immunol. 11:351-357.
43. O'Brien KL, et al. 2009. Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. Nat. Med. 15:873-875.
44. Perreau M, Pantaleo G, Kremer EJ. 2008. Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells. J. Exp. Med. 205:2717-2725.
45. Piedra PA, Poveda GA, Ramsey B, McCoy K, Hiatt PW. 1998. Incidence and prevalence of neutralizing antibodies to the common adenoviruses in children with cystic fibrosis: implication for gene therapy with adenovirus vectors. Pediatrics 101:1013-1019.
46. Qin L, Gilbert PB, Corey L, McElrath MJ, Self SG. 2007. A framework for assessing immunological correlates of protection in vaccine trials. J. Infect. Dis. 196:1304-1312.
47. Richardson C, et al. 2005. Susceptibility of B lymphocytes to adenovirus type 5 infection is dependent upon both coxsackie-adenovirus receptor and alphavbeta5 integrin expression. J. Gen. Virol. 86:1669-1679.
48. Sailaja G, HogenEsch H, North A, Hays J, Mittal SK. 2002. Encapsulation of recombinant adenovirus into alginate microspheres circumvents vector-specific immune response. Gene Ther. 9:1722-1729.
49. Shiver JW, et al. 2002. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency virus immunity. Nature 415: 331-335.
50. Shiver JW, Emini EA. 2004. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu. Rev. Med. 55:355-372.
51. Steinbrook R. 2007. One step forward, two steps back-will there ever be an AIDS vaccine? N. Engl. J. Med. 357:2653-2655.
52. Sumida SM, et al. 2004. Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J. Virol. 78:2666-2673.
53. Sun C, et al. 2010. Induction of balance and breadth in the immune responses is beneficial to control SIVmac239 replication in rhesus monkey. J. Infect. 60:371-381.
54. Sun C, et al. 2011. Epidemiology of adenovirus type 5 neutralizing antibodies in healthy people and AIDS patients in Guangzhou, southern China. Vaccine 29:3837-3841.
55. Tatsis N, Ertl HC. 2004. Adenoviruses as vaccine vectors. Mol. Ther. 10:616-629.
56. Tirado SM, Yoon KJ. 2003. Antibody-dependent enhancement of virus infection and disease. Viral Immunol. 16:69-86.
57. Thorner AR, et al. 2006. Age dependence of adenovirus-specific neutralizing antibody titers in individuals from Sub-Saharan Africa. J. Clin. Microbiol. 44:3781-3783.
58. Vogel TU, et al. 2003. Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239. J. Virol. 77: 13348-13360.
59. Vulink A, Radford KJ, Melief C, Hart DN. 2008. Dendritic cells in cancer immunotherapy. Adv. Cancer Res. 99:363-407.
60. Watkins DI, Burton DR, Kallas EG, Moore JP, Koff WC. 2008. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat. Med. 14:617-621.
61. Weaver EA, Barry MA. 2008. Effects of shielding adenoviral vectors with polyethylene glycol (PEG) on vector-specific and vaccine-mediated immune responses. Hum. Gene Ther. 19:1369-1382.
62. Wohlfart C. 1988. Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms. J. Virol. 62:2321-2328.
63. Xin KQ, et al. 2005. Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV. Gene Ther. 12:1769-1777.